Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A, Niederacher D, Fischer JC, Stoecklein NH, Ruckhaeberle E, Fehm T, Neubauer H.

Clin Chem. 2019 Feb 8. pii: clinchem.2018.296814. doi: 10.1373/clinchem.2018.296814. [Epub ahead of print]

PMID:
30737205
2.

Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.

Banys-Paluchowski M, Schneck H, Blassl C, Schultz S, Meier-Stiegen F, Niederacher D, Krawczyk N, Ruckhaeberle E, Fehm T, Neubauer H.

Geburtshilfe Frauenheilkd. 2015 Mar;75(3):232-237.

3.

Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.

Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, Fehm T.

Biomed Res Int. 2014;2014:415721. doi: 10.1155/2014/415721. Epub 2014 May 8. Review.

4.

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.

Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T.

Breast Cancer Res Treat. 2013 Jan;137(2):407-16. doi: 10.1007/s10549-012-2356-2. Epub 2012 Dec 16.

PMID:
23242614
5.

Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center.

Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E, Becker S, Serve H, Huebner J.

J Cancer Res Clin Oncol. 2013 Mar;139(3):357-65. doi: 10.1007/s00432-012-1336-6. Epub 2012 Oct 26.

PMID:
23099993
6.

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L.

Ann Surg Oncol. 2012 May;19(5):1508-16. doi: 10.1245/s10434-011-2108-2. Epub 2011 Dec 23.

PMID:
22193884
7.

A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.

8.

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.

Kaufmann M, Maass N, Costa SD, Schneeweiss A, Loibl S, Sütterlin MW, Schrader I, Gerber B, Bauer W, Wiest W, Tomé O, Distelrath A, Hagen V, Kleine-Tebbe A, Ruckhaeberle E, Mehta K, von Minckwitz G; GBG-39 Trialists.

Eur J Cancer. 2010 Dec;46(18):3184-91. doi: 10.1016/j.ejca.2010.07.009. Epub 2010 Aug 24.

PMID:
20797843
9.

Clinical relevance of the putative stem cell marker p63 in breast cancer.

Hanker L, Karn T, Ruckhaeberle E, Gaetje R, Solbach C, Schmidt M, Engels K, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Aug;122(3):765-75. doi: 10.1007/s10549-009-0608-6. Epub 2009 Nov 7.

PMID:
19898932
10.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.

11.

Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer.

Rody A, Karn T, Ruckhaeberle E, Hanker L, Gaetje R, Holtrich U, Kaufmann M.

Eur J Cancer. 2008 Sep;44(13):1789-92. doi: 10.1016/j.ejca.2008.06.037. Epub 2008 Aug 6.

PMID:
18691884

Supplemental Content

Loading ...
Support Center